Skip to main content

FDA Clears Ozanimod (Zeposia) for MS; COVID-19 Delays Launch

Ozanimod is the first oral, once-daily sphingosine-1-phosphate receptor modulator approved for adults with relapsing forms of multiple sclerosis.



from WebMD Health https://ift.tt/2WV1UH8
via IFTTT

Comments

Popular posts from this blog

The Future of Autoimmune Disorders: Psoriatic Disease

What's being done to help people with psoriatic disease? We get a look at the ever-changing picture from a rheumatologist. from WebMD Health https://ift.tt/5P6ZHyd via IFTTT

Long COVID Experts: ‘So Incredibly Clear What’s at Stake’

It’s estimated that more than a third of people who have had COVID-19 experience neurological complications such as brain fog that persist or develop 3 months after infection. And two thirds of so-called long haulers still have neurological symptoms after 6 months. from WebMD Health https://ift.tt/mx1j6QD via IFTTT

Study: Black Men Twice as Likely to Develop Prostate Cancer as Whites

A review of men seen at VA hospitals found that Black veterans had nearly twice the incidence of localized and advanced prostate cancer as white men. from WebMD Health https://ift.tt/3Knscs2 via IFTTT